Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
DHR vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
DHR vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $123.80B | $175.76B |
| Revenue (TTM) | $24.78B | $45.20B |
| Net Income (TTM) | $3.69B | $6.86B |
| Gross Margin | 60.7% | 39.4% |
| Operating Margin | 21.0% | 17.8% |
| Forward P/E | 20.7x | 19.0x |
| Total Debt | $18.42B | $40.85B |
| Cash & Equiv. | $4.62B | $9.86B |
DHR vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Danaher Corporation (DHR) | 100 | 118.4 | +18.4% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DHR vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DHR is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.94, yield 0.7%
- Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
- Beta 0.94, yield 0.7%, current ratio 1.87x
TMO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
- 229.1% 10Y total return vs DHR's 218.0%
- PEG 9.02 vs DHR's 34.20
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.9% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (19.0x vs 20.7x), PEG 9.02 vs 34.20 | |
| Quality / Margins | 15.2% margin vs DHR's 14.9% | |
| Stability / Safety | Beta 0.94 vs TMO's 1.10, lower leverage | |
| Dividends | 0.7% yield, 1-year raise streak, vs TMO's 0.4% | |
| Momentum (1Y) | +16.6% vs DHR's -7.2% | |
| Efficiency (ROA) | 6.4% ROA vs DHR's 4.5%, ROIC 7.5% vs 5.9% |
DHR vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DHR vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — DHR and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 1.8x DHR's $24.8B. Profitability is closely matched — net margins range from 15.2% (TMO) to 14.9% (DHR).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $24.8B | $45.2B |
| EBITDAEarnings before interest/tax | $7.2B | $10.5B |
| Net IncomeAfter-tax profit | $3.7B | $6.9B |
| Free Cash FlowCash after capex | $5.3B | $6.7B |
| Gross MarginGross profit ÷ Revenue | +60.7% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +21.0% | +17.8% |
| Net MarginNet income ÷ Revenue | +14.9% | +15.2% |
| FCF MarginFCF ÷ Revenue | +21.4% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.7% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.8% | +11.3% |
Valuation Metrics
TMO leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, TMO trades at a 23% valuation discount to DHR's 34.7x P/E. Adjusting for growth (PEG ratio), TMO offers better value at 12.62x vs DHR's 34.20x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||
|---|---|---|
| Market CapShares × price | $123.8B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $137.6B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 34.71x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.73x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | 34.20x | 12.62x |
| EV / EBITDAEnterprise value multiple | 18.14x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 5.04x | 3.94x |
| Price / BookPrice ÷ Book value/share | 2.37x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 23.54x | 27.93x |
Profitability & Efficiency
DHR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs TMO's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +7.1% | +13.2% |
| ROA (TTM)Return on assets | +4.5% | +6.4% |
| ROICReturn on invested capital | +5.9% | +7.5% |
| ROCEReturn on capital employed | +7.0% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.35x | 0.76x |
| Net DebtTotal debt minus cash | $13.8B | $31.0B |
| Cash & Equiv.Liquid assets | $4.6B | $9.9B |
| Total DebtShort + long-term debt | $18.4B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 18.13x | 5.89x |
Total Returns (Dividends Reinvested)
TMO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $7,907 for DHR. Over the past 12 months, TMO leads with a +16.6% total return vs DHR's -7.2%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs DHR's -5.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -23.9% | -20.1% |
| 1-Year ReturnPast 12 months | -7.2% | +16.6% |
| 3-Year ReturnCumulative with dividends | -15.9% | -11.9% |
| 5-Year ReturnCumulative with dividends | -20.9% | +2.1% |
| 10-Year ReturnCumulative with dividends | +218.0% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -5.6% | -4.2% |
Risk & Volatility
Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 1.10x |
| 52-Week HighHighest price in past year | $242.80 | $643.99 |
| 52-Week LowLowest price in past year | $172.06 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +72.0% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 32.3 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 1.9M |
Analyst Outlook
Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates DHR as "Buy" and TMO as "Buy". Consensus price targets imply 41.2% upside for DHR (target: $247) vs 38.4% for TMO (target: $655). For income investors, DHR offers the higher dividend yield at 0.71% vs TMO's 0.36%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $247.00 | $654.67 |
| # AnalystsCovering analysts | 42 | 42 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 8 |
| Dividend / ShareAnnual DPS | $1.23 | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.5% | +1.7% |
TMO leads in 2 of 6 categories (Valuation Metrics, Total Returns). DHR leads in 1 (Profitability & Efficiency). 3 tied.
DHR vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is DHR or TMO a better buy right now?
For growth investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DHR or TMO?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 7x versus Danaher Corporation at 34. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Thermo Fisher Scientific Inc. wins at 9. 02x versus Danaher Corporation's 34. 20x.
03Which is the better long-term investment — DHR or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -20. 9% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus DHR's +218. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DHR or TMO?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
94β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 17% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DHR or TMO?
By revenue growth (latest reported year), Thermo Fisher Scientific Inc.
(TMO) is pulling ahead at 3. 9% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DHR or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DHR or TMO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Thermo Fisher Scientific Inc. (TMO) is the more undervalued stock at a PEG of 9. 02x versus Danaher Corporation's 34. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 20. 7x for Danaher Corporation — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 41. 2% to $247. 00.
08Which pays a better dividend — DHR or TMO?
All stocks in this comparison pay dividends.
Danaher Corporation (DHR) offers the highest yield at 0. 7%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).
09Is DHR or TMO better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
94), 0. 7% yield, +218. 0% 10Y return). Both have compounded well over 10 years (DHR: +218. 0%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DHR and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
DHR pays a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.